ORGOOrganogenesis Holdings Inc.

Nasdaq organogenesis.com


$ 3.04 $ 0.75 (32.89 %)    

Friday, 10-May-2024 15:59:55 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 3.03
$ 2.73
$ 0.00 x 0
$ 0.00 x 0
$ 2.73 - $ 3.12
$ 1.96 - $ 4.71
3,545,736
na
399.54M
$ 1.17
$ 68.72
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-09-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-14-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-28-2017 12-31-2016 10-K
31 11-18-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 organogenesis-hldgs-q1-2024-adj-eps-001-beats-003-estimate-sales-109976m-beat-101050m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $...

 organogenesis-achieves-primary-endpoint-in-phase-3-clinical-trial-of-renu-for-knee-osteoarthritis

 Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance o...

 cantor-fitzgerald-reiterates-overweight-on-organogenesis-hldgs-maintains-5-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Hldgs (NASDAQ:ORGO) with a Overweight and maintains $5 price ...

 organogenesis-hldgs-q4-2023-gaap-eps-0010-inline-sales-99651m-miss-109050m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.010 per share which met the analyst consensus estimate. Th...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 cantor-fitzgerald-initiates-coverage-on-organogenesis-hldgs-with-overweight-rating-announces-price-target-of-5

Cantor Fitzgerald analyst Ross Osborn initiates coverage on Organogenesis Hldgs (NASDAQ:ORGO) with a Overweight rating and a...

 why-reneo-pharmaceuticals-shares-are-trading-higher-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an ac...

 meta-to-rally-over-18-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 btig-maintains-buy-on-organogenesis-hldgs-raises-price-target-to-6

BTIG analyst Ryan Zimmerman maintains Organogenesis Hldgs (NASDAQ:ORGO) with a Buy and raises the price target from $4 to $6.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION